BRAF-Mutant NSCLCÂ
BRAF mutations have been identified in 2% of patients with NSCLC, half
of whom have a BRAF V600E mutation. In these patients, the response rate
was 63.2%, and median PFS was 9.7 months after treatment with a
combination of the BRAF inhibitor dabrafenib and the MEK inhibitor
trametinib[68].A response rate of 42% and median PFS of 7.3 months
were reported after treatment with vemurafenib, another BRAF inhibitor
[69].These data strongly recommend using targeted therapy to
treating patients with BRAF-mutant lung cancer for better clinical
outcomes .